Cargando…

Therapeutic Potential of Targeting ß-Arrestin

ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Bond, Richard A., Lucero Garcia-Rojas, Emilio Y., Hegde, Akhil, Walker, Julia K. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414794/
https://www.ncbi.nlm.nih.gov/pubmed/30894814
http://dx.doi.org/10.3389/fphar.2019.00124
_version_ 1783403042086846464
author Bond, Richard A.
Lucero Garcia-Rojas, Emilio Y.
Hegde, Akhil
Walker, Julia K. L.
author_facet Bond, Richard A.
Lucero Garcia-Rojas, Emilio Y.
Hegde, Akhil
Walker, Julia K. L.
author_sort Bond, Richard A.
collection PubMed
description ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent signaling, initiation of ß-arrestin-dependent signaling, receptor trafficking to degradative or recycling pathways, receptor transactivation, transcriptional regulation, and localization of second messenger regulators. The pleiotropic influence ß-arrestins exert on these receptors regulates a breadth of physiological functions, and additionally, ß-arrestins are involved in the pathophysiology of numerous and wide-ranging diseases, making them prime therapeutic targets. In this review, we briefly describe the mechanisms by which ß-arrestins regulate GPCR signaling, including the functional cellular mechanisms modulated by ß-arrestins and relate this to observed pathophysiological responses associated with ß-arrestins. We focus on the role for ß-arrestins in transducing cell signaling; a pathway that is complementary to the classical G protein-coupling pathway. The existence of these GPCR dual signaling pathways offers an immense therapeutic opportunity through selective targeting of one signaling pathway over the other. Finally, we will consider several mechanisms by which the potential of dual signaling pathway regulation can be harnessed and the implications for improved disease treatments.
format Online
Article
Text
id pubmed-6414794
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64147942019-03-20 Therapeutic Potential of Targeting ß-Arrestin Bond, Richard A. Lucero Garcia-Rojas, Emilio Y. Hegde, Akhil Walker, Julia K. L. Front Pharmacol Pharmacology ß-arrestins are multifunctional proteins that modulate heptahelical 7 transmembrane receptors, also known as G protein-coupled receptors (GPCRs), a superfamily of receptors that regulate most physiological processes. ß-arrestin modulation of GPCR function includes termination of G protein-dependent signaling, initiation of ß-arrestin-dependent signaling, receptor trafficking to degradative or recycling pathways, receptor transactivation, transcriptional regulation, and localization of second messenger regulators. The pleiotropic influence ß-arrestins exert on these receptors regulates a breadth of physiological functions, and additionally, ß-arrestins are involved in the pathophysiology of numerous and wide-ranging diseases, making them prime therapeutic targets. In this review, we briefly describe the mechanisms by which ß-arrestins regulate GPCR signaling, including the functional cellular mechanisms modulated by ß-arrestins and relate this to observed pathophysiological responses associated with ß-arrestins. We focus on the role for ß-arrestins in transducing cell signaling; a pathway that is complementary to the classical G protein-coupling pathway. The existence of these GPCR dual signaling pathways offers an immense therapeutic opportunity through selective targeting of one signaling pathway over the other. Finally, we will consider several mechanisms by which the potential of dual signaling pathway regulation can be harnessed and the implications for improved disease treatments. Frontiers Media S.A. 2019-03-06 /pmc/articles/PMC6414794/ /pubmed/30894814 http://dx.doi.org/10.3389/fphar.2019.00124 Text en Copyright © 2019 Bond, Lucero Garcia-Rojas, Hegde and Walker. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Bond, Richard A.
Lucero Garcia-Rojas, Emilio Y.
Hegde, Akhil
Walker, Julia K. L.
Therapeutic Potential of Targeting ß-Arrestin
title Therapeutic Potential of Targeting ß-Arrestin
title_full Therapeutic Potential of Targeting ß-Arrestin
title_fullStr Therapeutic Potential of Targeting ß-Arrestin
title_full_unstemmed Therapeutic Potential of Targeting ß-Arrestin
title_short Therapeutic Potential of Targeting ß-Arrestin
title_sort therapeutic potential of targeting ß-arrestin
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414794/
https://www.ncbi.nlm.nih.gov/pubmed/30894814
http://dx.doi.org/10.3389/fphar.2019.00124
work_keys_str_mv AT bondricharda therapeuticpotentialoftargetingßarrestin
AT lucerogarciarojasemilioy therapeuticpotentialoftargetingßarrestin
AT hegdeakhil therapeuticpotentialoftargetingßarrestin
AT walkerjuliakl therapeuticpotentialoftargetingßarrestin